Autoantibody Formation in Human and Rat Studies of Chronic Rejection and Primary Graft Dysfunction
Overview
Authors
Affiliations
Lung transplantation is considered a definitive treatment for many lung diseases. However, rejection and other pathologic entities are major causes of morbidity and mortality for lung transplant recipients. Primary graft dysfunction (PGD) and obliterative bronchiolitis (OB) are the leading causes of early and late mortality, respectively. While the immune basis of PGD has not been clearly defined, evidence is emerging about roles for autoantibodies in this process. Similarly, the pathogenesis of OB has been linked recently to autoimmunity. This review will highlight the current understanding of autoantibodies in PGD and OB post lung transplantation.
Dugbartey G Mol Biol Rep. 2024; 51(1):473.
PMID: 38553658 PMC: 10980643. DOI: 10.1007/s11033-024-09261-7.
Antibody-Mediated Rejection: Diagnosis and Treatment.
Halverson L, Hachem R Clin Chest Med. 2023; 44(1):95-103.
PMID: 36774172 PMC: 10148231. DOI: 10.1016/j.ccm.2022.10.008.
Yang W, Cerier E, Nunez-Santana F, Wu Q, Yan Y, Kurihara C J Clin Invest. 2022; 132(20).
PMID: 36250462 PMC: 9566897. DOI: 10.1172/JCI157975.
Clinical relevance of lung-restricted antibodies in lung transplantation.
Akbarpour M, Wu Q, Liu X, Sun H, Lecuona E, Tomic R Hum Immunol. 2019; 80(8):595-601.
PMID: 31078336 PMC: 6844365. DOI: 10.1016/j.humimm.2019.04.016.
Diagnosis, Pathophysiology and Experimental Models of Chronic Lung Allograft Rejection.
Gauthier J, Ruiz-Perez D, Li W, Hachem R, Puri V, Gelman A Transplantation. 2018; 102(9):1459-1466.
PMID: 29683998 PMC: 6884147. DOI: 10.1097/TP.0000000000002250.